PMC:7228307 / 58074-58419 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1188","span":{"begin":250,"end":254},"obj":"Gene"},{"id":"1189","span":{"begin":327,"end":330},"obj":"Gene"},{"id":"1190","span":{"begin":332,"end":335},"obj":"Gene"},{"id":"1191","span":{"begin":243,"end":248},"obj":"Gene"},{"id":"1192","span":{"begin":289,"end":294},"obj":"Disease"},{"id":"1193","span":{"begin":308,"end":314},"obj":"Disease"}],"attributes":[{"id":"A1188","pred":"tao:has_database_id","subj":"1188","obj":"Gene:7293"},{"id":"A1189","pred":"tao:has_database_id","subj":"1189","obj":"Gene:3126"},{"id":"A1190","pred":"tao:has_database_id","subj":"1190","obj":"Gene:8795"},{"id":"A1191","pred":"tao:has_database_id","subj":"1191","obj":"Gene:3604"},{"id":"A1192","pred":"tao:has_database_id","subj":"1192","obj":"MESH:D003643"},{"id":"A1193","pred":"tao:has_database_id","subj":"1193","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T448","span":{"begin":42,"end":47},"obj":"Body_part"},{"id":"T449","span":{"begin":195,"end":219},"obj":"Body_part"},{"id":"T450","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T451","span":{"begin":225,"end":230},"obj":"Body_part"},{"id":"T452","span":{"begin":315,"end":320},"obj":"Body_part"}],"attributes":[{"id":"A448","pred":"fma_id","subj":"T448","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A449","pred":"fma_id","subj":"T449","obj":"http://purl.org/sig/ont/fma/fma273565"},{"id":"A450","pred":"fma_id","subj":"T450","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A451","pred":"fma_id","subj":"T451","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A452","pred":"fma_id","subj":"T452","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T111","span":{"begin":308,"end":314},"obj":"Disease"}],"attributes":[{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T972","span":{"begin":42,"end":47},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T973","span":{"begin":63,"end":72},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T974","span":{"begin":214,"end":219},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T975","span":{"begin":223,"end":230},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T976","span":{"begin":315,"end":320},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T977","span":{"begin":342,"end":345},"obj":"http://purl.obolibrary.org/obo/CLO_0001046"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T38447","span":{"begin":182,"end":191},"obj":"Chemical"},{"id":"T65735","span":{"begin":195,"end":202},"obj":"Chemical"}],"attributes":[{"id":"A49680","pred":"chebi_id","subj":"T38447","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A76938","pred":"chebi_id","subj":"T65735","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T247","span":{"begin":42,"end":47},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T248","span":{"begin":214,"end":219},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T249","span":{"begin":225,"end":230},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T250","span":{"begin":315,"end":320},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T106","span":{"begin":0,"end":9},"obj":"JJ"},{"id":"T107","span":{"begin":10,"end":14},"obj":"NNS"},{"id":"T108","span":{"begin":15,"end":21},"obj":"VBP"},{"id":"T109","span":{"begin":22,"end":31},"obj":"NNS"},{"id":"T110","span":{"begin":32,"end":34},"obj":"IN"},{"id":"T111","span":{"begin":35,"end":41},"obj":"NN"},{"id":"T112","span":{"begin":42,"end":47},"obj":"NNS"},{"id":"T113","span":{"begin":48,"end":50},"obj":"IN"},{"id":"T114","span":{"begin":51,"end":62},"obj":"VBG"},{"id":"T115","span":{"begin":63,"end":72},"obj":"NN"},{"id":"T116","span":{"begin":73,"end":75},"obj":"IN"},{"id":"T117","span":{"begin":76,"end":81},"obj":"PRP-DOLLAR-"},{"id":"T118","span":{"begin":82,"end":91},"obj":"JJ"},{"id":"T119","span":{"begin":92,"end":98},"obj":"NN"},{"id":"T120","span":{"begin":100,"end":109},"obj":"RB"},{"id":"T121","span":{"begin":109,"end":110},"obj":"-COMMA-"},{"id":"T122","span":{"begin":111,"end":115},"obj":"DT"},{"id":"T123","span":{"begin":116,"end":118},"obj":"VBZ"},{"id":"T124","span":{"begin":119,"end":121},"obj":"TO"},{"id":"T125","span":{"begin":122,"end":128},"obj":"CC"},{"id":"T126","span":{"begin":129,"end":136},"obj":"VB"},{"id":"T127","span":{"begin":137,"end":146},"obj":"NN"},{"id":"T128","span":{"begin":147,"end":155},"obj":"NN"},{"id":"T129","span":{"begin":156,"end":158},"obj":"IN"},{"id":"T130","span":{"begin":159,"end":167},"obj":"VBG"},{"id":"T131","span":{"begin":168,"end":181},"obj":"JJ"},{"id":"T132","span":{"begin":182,"end":191},"obj":"NNS"},{"id":"T133","span":{"begin":192,"end":194},"obj":"IN"},{"id":"T134","span":{"begin":195,"end":213},"obj":"JJ"},{"id":"T135","span":{"begin":214,"end":219},"obj":"NNS"},{"id":"T136","span":{"begin":220,"end":222},"obj":"CC"},{"id":"T137","span":{"begin":223,"end":224},"obj":"NN"},{"id":"T138","span":{"begin":225,"end":230},"obj":"NNS"},{"id":"T139","span":{"begin":231,"end":232},"obj":"-LRB-"},{"id":"T140","span":{"begin":232,"end":236},"obj":"FW"},{"id":"T141","span":{"begin":237,"end":241},"obj":"NN"},{"id":"T142","span":{"begin":241,"end":242},"obj":"-COMMA-"},{"id":"T143","span":{"begin":243,"end":248},"obj":"NN"},{"id":"T144","span":{"begin":248,"end":249},"obj":"-COMMA-"},{"id":"T145","span":{"begin":250,"end":254},"obj":"NN"},{"id":"T146","span":{"begin":254,"end":255},"obj":"-RRB-"},{"id":"T147","span":{"begin":256,"end":258},"obj":"CC"},{"id":"T148","span":{"begin":259,"end":266},"obj":"VB"},{"id":"T149","span":{"begin":267,"end":276},"obj":"NN"},{"id":"T150","span":{"begin":277,"end":279},"obj":"IN"},{"id":"T151","span":{"begin":280,"end":288},"obj":"VBG"},{"id":"T152","span":{"begin":289,"end":294},"obj":"NN"},{"id":"T153","span":{"begin":295,"end":304},"obj":"NNS"},{"id":"T154","span":{"begin":305,"end":307},"obj":"IN"},{"id":"T155","span":{"begin":308,"end":314},"obj":"NN"},{"id":"T156","span":{"begin":315,"end":320},"obj":"NNS"},{"id":"T157","span":{"begin":321,"end":322},"obj":"-LRB-"},{"id":"T158","span":{"begin":322,"end":326},"obj":"FW"},{"id":"T159","span":{"begin":327,"end":330},"obj":"NN"},{"id":"T160","span":{"begin":330,"end":331},"obj":"-COMMA-"},{"id":"T161","span":{"begin":332,"end":335},"obj":"NN"},{"id":"T162","span":{"begin":335,"end":336},"obj":"-COMMA-"},{"id":"T163","span":{"begin":337,"end":340},"obj":"NN"},{"id":"T164","span":{"begin":340,"end":341},"obj":"-RRB-"}],"relations":[{"id":"R108","pred":"arg1Of","subj":"T107","obj":"T106"},{"id":"R109","pred":"arg1Of","subj":"T107","obj":"T108"},{"id":"R110","pred":"arg2Of","subj":"T109","obj":"T108"},{"id":"R111","pred":"arg1Of","subj":"T109","obj":"T110"},{"id":"R112","pred":"arg2Of","subj":"T112","obj":"T110"},{"id":"R113","pred":"arg1Of","subj":"T112","obj":"T111"},{"id":"R114","pred":"arg1Of","subj":"T108","obj":"T113"},{"id":"R115","pred":"arg2Of","subj":"T114","obj":"T113"},{"id":"R116","pred":"arg1Of","subj":"T107","obj":"T114"},{"id":"R117","pred":"arg2Of","subj":"T115","obj":"T114"},{"id":"R118","pred":"arg1Of","subj":"T115","obj":"T116"},{"id":"R119","pred":"arg2Of","subj":"T119","obj":"T116"},{"id":"R120","pred":"arg1Of","subj":"T119","obj":"T117"},{"id":"R121","pred":"arg1Of","subj":"T119","obj":"T118"},{"id":"R122","pred":"arg1Of","subj":"T123","obj":"T120"},{"id":"R123","pred":"arg1Of","subj":"T123","obj":"T121"},{"id":"R124","pred":"arg1Of","subj":"T122","obj":"T123"},{"id":"R125","pred":"arg2Of","subj":"T147","obj":"T123"},{"id":"R126","pred":"arg1Of","subj":"T147","obj":"T124"},{"id":"R127","pred":"arg1Of","subj":"T147","obj":"T125"},{"id":"R128","pred":"arg2Of","subj":"T128","obj":"T126"},{"id":"R129","pred":"arg1Of","subj":"T128","obj":"T127"},{"id":"R130","pred":"arg1Of","subj":"T126","obj":"T129"},{"id":"R131","pred":"arg2Of","subj":"T130","obj":"T129"},{"id":"R132","pred":"arg2Of","subj":"T132","obj":"T130"},{"id":"R133","pred":"arg1Of","subj":"T132","obj":"T131"},{"id":"R134","pred":"arg1Of","subj":"T132","obj":"T133"},{"id":"R135","pred":"arg2Of","subj":"T136","obj":"T133"},{"id":"R136","pred":"arg1Of","subj":"T135","obj":"T134"},{"id":"R137","pred":"arg1Of","subj":"T135","obj":"T136"},{"id":"R138","pred":"arg2Of","subj":"T138","obj":"T136"},{"id":"R139","pred":"arg1Of","subj":"T138","obj":"T137"},{"id":"R140","pred":"arg1Of","subj":"T136","obj":"T139"},{"id":"R141","pred":"arg2Of","subj":"T142","obj":"T139"},{"id":"R142","pred":"arg3Of","subj":"T146","obj":"T139"},{"id":"R143","pred":"arg1Of","subj":"T142","obj":"T140"},{"id":"R144","pred":"arg1Of","subj":"T141","obj":"T142"},{"id":"R145","pred":"arg2Of","subj":"T143","obj":"T142"},{"id":"R146","pred":"arg1Of","subj":"T142","obj":"T144"},{"id":"R147","pred":"arg2Of","subj":"T145","obj":"T144"},{"id":"R148","pred":"arg1Of","subj":"T126","obj":"T147"},{"id":"R149","pred":"arg2Of","subj":"T148","obj":"T147"},{"id":"R150","pred":"arg2Of","subj":"T149","obj":"T148"},{"id":"R151","pred":"arg1Of","subj":"T148","obj":"T150"},{"id":"R152","pred":"arg2Of","subj":"T151","obj":"T150"},{"id":"R153","pred":"arg2Of","subj":"T153","obj":"T151"},{"id":"R154","pred":"arg1Of","subj":"T153","obj":"T152"},{"id":"R155","pred":"arg1Of","subj":"T153","obj":"T154"},{"id":"R156","pred":"arg2Of","subj":"T156","obj":"T154"},{"id":"R157","pred":"arg1Of","subj":"T156","obj":"T155"},{"id":"R158","pred":"arg1Of","subj":"T156","obj":"T157"},{"id":"R159","pred":"arg2Of","subj":"T159","obj":"T157"},{"id":"R160","pred":"arg3Of","subj":"T164","obj":"T157"},{"id":"R161","pred":"arg1Of","subj":"T159","obj":"T158"},{"id":"R162","pred":"arg1Of","subj":"T159","obj":"T160"},{"id":"R163","pred":"arg2Of","subj":"T161","obj":"T160"},{"id":"R164","pred":"arg1Of","subj":"T159","obj":"T162"},{"id":"R165","pred":"arg2Of","subj":"T163","obj":"T162"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1188","span":{"begin":250,"end":254},"obj":"Gene"},{"id":"1189","span":{"begin":327,"end":330},"obj":"Gene"},{"id":"1190","span":{"begin":332,"end":335},"obj":"Gene"},{"id":"1191","span":{"begin":243,"end":248},"obj":"Gene"},{"id":"1192","span":{"begin":289,"end":294},"obj":"Disease"},{"id":"1193","span":{"begin":308,"end":314},"obj":"Disease"}],"attributes":[{"id":"A1189","pred":"pubann:denotes","subj":"1189","obj":"Gene:3126"},{"id":"A1190","pred":"pubann:denotes","subj":"1190","obj":"Gene:8795"},{"id":"A1193","pred":"pubann:denotes","subj":"1193","obj":"MESH:D009369"},{"id":"A1188","pred":"pubann:denotes","subj":"1188","obj":"Gene:7293"},{"id":"A1191","pred":"pubann:denotes","subj":"1191","obj":"Gene:3604"},{"id":"A1192","pred":"pubann:denotes","subj":"1192","obj":"MESH:D003643"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T322","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T323","span":{"begin":100,"end":345},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T738","span":{"begin":168,"end":191},"obj":"Protein"},{"id":"T747","span":{"begin":237,"end":241},"obj":"Protein"}],"attributes":[{"id":"A738","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q9BXR1"},{"id":"A739","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q8VE98"},{"id":"A740","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q8NCB6"},{"id":"A741","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q8NC34"},{"id":"A742","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q8NBI8"},{"id":"A743","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q7TPB4"},{"id":"A744","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q6UXI2"},{"id":"A745","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q6P5Y4"},{"id":"A746","pred":"uniprot_id","subj":"T738","obj":"https://www.uniprot.org/uniprot/Q5ZPR3"},{"id":"A747","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q9BYU0"},{"id":"A748","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q99NE3"},{"id":"A749","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q99NE2"},{"id":"A750","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q99NE1"},{"id":"A751","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q99NE0"},{"id":"A752","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q8SQ34"},{"id":"A753","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q8K2X6"},{"id":"A754","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q86YK5"},{"id":"A755","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q7YRL5"},{"id":"A756","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q7M4Q8"},{"id":"A757","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q5U007"},{"id":"A758","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q5JY15"},{"id":"A759","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q542B1"},{"id":"A760","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q53GN5"},{"id":"A761","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3ZTK5"},{"id":"A762","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3UBH3"},{"id":"A763","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3U7C9"},{"id":"A764","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3U799"},{"id":"A765","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3TSL2"},{"id":"A766","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3TS33"},{"id":"A767","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q3LRP1"},{"id":"A768","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/Q28203"},{"id":"A769","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/P27512"},{"id":"A770","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/P25942"},{"id":"A771","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/E1P5S9"},{"id":"A772","pred":"uniprot_id","subj":"T747","obj":"https://www.uniprot.org/uniprot/A7YWS9"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T447","span":{"begin":42,"end":47},"obj":"Body_part"},{"id":"T448","span":{"begin":195,"end":219},"obj":"Body_part"},{"id":"T449","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T450","span":{"begin":225,"end":230},"obj":"Body_part"},{"id":"T451","span":{"begin":315,"end":320},"obj":"Body_part"}],"attributes":[{"id":"A450","pred":"fma_id","subj":"T450","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A447","pred":"fma_id","subj":"T447","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A448","pred":"fma_id","subj":"T448","obj":"http://purl.org/sig/ont/fma/fma273565"},{"id":"A449","pred":"fma_id","subj":"T449","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A451","pred":"fma_id","subj":"T451","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T132","span":{"begin":63,"end":72},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T133","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0006915"},{"id":"T134","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T135","span":{"begin":289,"end":294},"obj":"http://purl.obolibrary.org/obo/GO_0016265"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T48","span":{"begin":308,"end":314},"obj":"Disease"}],"attributes":[{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T43","span":{"begin":308,"end":314},"obj":"Phenotype"}],"attributes":[{"id":"A43","pred":"hp_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T132","span":{"begin":63,"end":72},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T133","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T134","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0006915"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T132","span":{"begin":63,"end":72},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T133","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T134","span":{"begin":267,"end":276},"obj":"http://purl.obolibrary.org/obo/GO_0006915"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-sentences","denotations":[{"id":"T322","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T323","span":{"begin":100,"end":345},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T43","span":{"begin":308,"end":314},"obj":"Phenotype"}],"attributes":[{"id":"A43","pred":"hp_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target. Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116"}